MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Incompatible

Mycophenolate mofetil 500mg tablets (Tillomed Laboratories Ltd)

Explore other Mycophenolate mofetil formulations Explore other Mycophenolate mofetil 500mg tablets suppliers

Stability Notes

Store in original package to protect from moisture.

Provenance

Compatibility information derived from CellCept 500mg tablets (Roche Products Ltd).

Incompatible

Mycophenolic acid 180mg gastro-resistant tablets (A A H Pharmaceuticals Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 180mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatiblity information derived from Myfortic 180mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

Incompatible

Mycophenolic acid 180mg gastro-resistant tablets (Accord-UK Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 180mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatiblity information derived from Myfortic 180mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

Incompatible

Mycophenolic acid 360mg gastro-resistant tablets (A A H Pharmaceuticals Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 360mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatibility information derived from Myfortic 360mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

Incompatible

Mycophenolic acid 360mg gastro-resistant tablets (Accord-UK Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 360mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatibility information derived from Myfortic 360mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

No Stability Information

Mydriasert 5.4mg/0.28mg ophthalmic inserts (Thea Pharmaceuticals Ltd)

Explore other Phenylephrine + Tropicamide formulations Explore other Phenylephrine 5.4mg / Tropicamide 0.28mg ophthalmic inserts preservative free suppliers

Stability Notes

There are no stability notes available for this medicine.

Incompatible

Myfenax 250mg capsules (Teva UK Ltd)

Explore other Mycophenolate mofetil formulations Explore other Mycophenolate mofetil 250mg capsules suppliers

Stability Notes

Store in original package to protect from moisture.

Provenance

Compatibility information derived from CellCept 250mg capsules (Roche Prodcts Ltd).

Incompatible

Myfenax 500mg tablets (Teva UK Ltd)

Explore other Mycophenolate mofetil formulations Explore other Mycophenolate mofetil 500mg tablets suppliers

Stability Notes

Store in original package to protect from moisture.

Provenance

Compatibility information derived from CellCept 500mg tablets (Roche Products Ltd).

Incompatible

Myfortic 180mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 180mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatiblity information derived from Myfortic 180mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

Incompatible

Myfortic 360mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd)

Explore other Mycophenolic acid formulations Explore other Mycophenolic acid 360mg gastro-resistant tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Airtight container. Teratogenic.

Provenance

Compatibility information derived from Myfortic 360mg gastro-resistant tablets (Novartis Pharmaceuticals UK Ltd).

Use with caution

Mylatrip 2.5mg tablets (Necessity Supplies Ltd)

Explore other Frovatriptan formulations Explore other Frovatriptan 2.5mg tablets suppliers

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Migard 2.5mg tablets (A. Menarini Farmaceutica Internazionale SRL).

Use with caution

Mylatrip 2.5mg tablets (Viatris UK Healthcare Ltd)

Explore other Frovatriptan formulations Explore other Frovatriptan 2.5mg tablets suppliers

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Migard 2.5mg tablets (A. Menarini Farmaceutica Internazionale SRL).

Use with caution

Myloxifin 10mg/5mg modified-release tablets (Ridge Pharma Ltd)

Explore other Oxycodone + Naloxone formulations Explore other Oxycodone 10mg / Naloxone 5mg modified-release tablets suppliers

Stability Notes

Airtight container. Protect from light.

Provenance

Compatiblity recommendation derived from Napp Pharmaceuticals Ltd product.

Use with caution

Myloxifin 20mg/10mg modified-release tablets (Ridge Pharma Ltd)

Explore other Oxycodone + Naloxone formulations Explore other Oxycodone 20mg / Naloxone 10mg modified-release tablets suppliers

Stability Notes

Airtight container. Protect from light.

Provenance

Compatiblity recommendation derived from Napp Pharmaceuticals Ltd product.

Use with caution

Myloxifin 40mg/20mg modified-release tablets (Ridge Pharma Ltd)

Explore other Oxycodone + Naloxone formulations Explore other Oxycodone 40mg / Naloxone 20mg modified-release tablets suppliers

Stability Notes

Airtight container. Protect from light.

Provenance

Compatiblity recommendation derived from Napp Pharmaceuticals Ltd product.

Print this list

Compatible

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.

Use with caution

Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.

Incompatible

Medicines under this category are not suitable for use inside MCAs.

No Stability Information

We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.